Table 1.
Summary of the results
| Diagnosis | Perifascicular atrophya | Perifascicular atrophy (2 rows) | RIG-I+ | Total | |
|---|---|---|---|---|---|
| Inflammatory myopathy (n = 71) | DM | 16 (36%) | 11 (25%) | 22 (50%) | 44 |
| PM | 0 (0%) | 0 (0%) | 0 (0%) | 16 | |
| IBM | 0 (0%) | 0 (0%) | 2 (33%) | 6 | |
| IMNM | 0 (0%) | 0 (0%) | 0 (0%) | 5 | |
| Overlapped myopathy (n = 26) | ASSb | 7 (88%) | 1 (13%) | 1 (13%) | 8 |
| RA | 0 (0%) | 0 (0%) | 1 (50%) | 2 | |
| SLE | 1 (50%) | 1 (50%) | 1 (50%) | 2 | |
| SSc | 3 (60%) | 2 (40%) | 1 (20%) | 5 | |
| Sjögren | 1 (20%) | 0 (0%) | 0 (0%) | 5 | |
| MCTD | 1 (25%) | 1 (25%) | 1 (25%) | 4 | |
| Muscle dystrophy (n = 8) | Dysf | 0 (0%) | 0 (0%) | 0 (0%) | 4 |
| FSHD | 0 (0%) | 0 (0%) | 0 (0%) | 4 | |
| Total | 29 (28%) | 16 (15%) | 29 (28%) | 105 | |
Healthy controls were excluded from this analysis. DM dermatomyositis, PM polymyositis, IBM inclusion body myositis, IMNM immune-mediated necrotizing myopathy, ASS anti-synthetase syndrome, RA rheumatoid arthritis, SLE systemic lupus erythematosus, SSc scleroderma and scleromyositis, MCTD mixed connective tissue disease, Dysf dysferlinopathy, FSHD fascioscapulohumeral muscle dystrophy. aPerifasicular atrophy includes one or more rows of atrophic muscle fibers. bThe group of ASS patients was established by the presence of anti-Jo-1 antibodies